The specter of generic rivalry has long loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the future of related pharmaceutical ventures. While initial years saw substantial profits, the patent end has allowed the door for discounted copies, possibly lowering earnings and creating a genuine danger for stakeholders